<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03598608</url>
  </required_header>
  <id_info>
    <org_study_id>4280-003</org_study_id>
    <secondary_id>MK-4280-003</secondary_id>
    <secondary_id>2018-001461-16</secondary_id>
    <nct_id>NCT03598608</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Safety and Efficacy of a Combination of Favezelimab (MK-4280) and Pembrolizumab (MK-3475) in Participants With Hematologic Malignancies (MK-4280-003)</brief_title>
  <official_title>A Phase 1/Phase 2 Clinical Study to Evaluate the Safety and Efficacy of a Combination of MK-4280 and Pembrolizumab (MK-3475) in Participants With Hematologic Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety and efficacy of favezelimab in combination with&#xD;
      pembrolizumab (MK-3475) in participants with hematological malignancies:&#xD;
&#xD;
        -  classical Hodgkin lymphoma (cHL)&#xD;
&#xD;
        -  diffuse large B-cell lymphoma (DLBCL)&#xD;
&#xD;
        -  indolent non-Hodgkin lymphoma (iNHL) The study will have 2 phases: a safety lead-in and&#xD;
           an efficacy expansion phase. The recommended Phase 2 dose (RPTD) will be determined in&#xD;
           the safety lead-in phase by evaluating dose-limiting toxicities.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 17, 2018</start_date>
  <completion_date type="Anticipated">August 30, 2026</completion_date>
  <primary_completion_date type="Anticipated">August 30, 2026</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Experiencing a Dose-limiting Toxicity (DLT)</measure>
    <time_frame>Cycle 1 (up to 21 days)</time_frame>
    <description>Percentage of participants experiencing a DLT defined by the National Cancer Institute Common Terminology for Adverse Events version 4.0 as:&#xD;
grade (gr) 4 non-hematologic toxicity (not laboratory)&#xD;
gr 4 hematologic toxicity lasting &gt;7 days OR gr 4 platelet count decreased of any duration OR gr 3 platelet count decreased if associated with bleeding&#xD;
any gr 3 non-hematologic toxicity (not laboratory) with the exception of gr 3 nausea, vomiting, or diarrhea (not be considered a DLT unless lasting &gt;3 days despite optimal supportive care)&#xD;
any gr 3 or 4 non-hematologic laboratory abnormality if medical intervention is required, or the abnormality leads to hospitalization, or the abnormality persists for &gt;1 week&#xD;
gr 3 or 4 febrile neutropenia&#xD;
any treatment-related AE which caused participant to discontinue study intervention during the first cycle&#xD;
gr 5 toxicity&#xD;
any treatment-related toxicity which causes a &gt;2-week delay in initiation of Cycle 2</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Experiencing an Adverse Event (AE)</measure>
    <time_frame>From time of signing informed consent form (ICF) until the end of follow-up (up to approximately 27 months)</time_frame>
    <description>Percentage of participants experiencing an AE defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study therapy and irrespective of causality to study treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants with Treatment Discontinuations Due to an AE</measure>
    <time_frame>From time of signing informed consent form (ICF) until the end of study treatment (up to approximately 24 months)</time_frame>
    <description>Percentage of participants discontinuing study treatment due to an AE</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>Up to approximately 24 months</time_frame>
    <description>ORR is defined as the percentage of participants in the analysis population who had a Complete Response (CR: Disappearance of all evidence of disease) or a Partial Response (PR: ≥50% decrease in sum of the product of the diameters (SPD) of up to six of the largest dominant nodes or nodal masses; no increase should be observed in the size of other nodes, liver, or spleen; and splenic and hepatic nodules must regress by ≥50% in their SPD or, for single nodules, in the greatest transverse diameter) per lymphoma disease response criteria (Cheson et. al., 2007) as assessed by the investigator.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Concentration of Favezelimab</measure>
    <time_frame>At designated time points (Up to approximately 25 months)</time_frame>
    <description>Blood samples will be collected at designated time points for the determination of the serum concentration of favezelimab. For Cycles 1 and 8: Day 1 at predose, end of infusion, and 4 hours postdose; Days 8 and 15 at any time. Cycles 2 through 7, Cycles 9 through 16 and every 4 cycles thereafter: Day 1 at predose. Blood samples will also be collected at the 30-day follow-up visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Concentration of Pembrolizumab</measure>
    <time_frame>At designated time points (Up to approximately 25 months)</time_frame>
    <description>Blood samples will be collected at designated time points for the determination of the serum concentration of pembrolizumab. For Cycles 1 and 8: Day 1 at predose, end of infusion, and 4 hours postdose; Days 8 and 15 at any time. Cycles 2 through 7, Cycles 9 through 16 and every 4 cycles thereafter: Day 1 at predose. Blood samples will also be collected at the 30-day follow-up visit.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">134</enrollment>
  <condition>Hodgkin Disease</condition>
  <condition>Lymphoma, Non-Hodgkin</condition>
  <condition>Lymphoma, B-Cell</condition>
  <arm_group>
    <arm_group_label>Part A: Favezelimab Dose A+pembrolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive 200 mg pembrolizumab by intravenous (IV) infusion followed by favezelimab Dose A by IV infusion on Day 1 of each 3-week cycle for up to 35 cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A: Favezelimab Dose B+pembrolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive 200 mg pembrolizumab by IV infusion followed by favezelimab Dose B by IV infusion on Day 1 of each 3-week cycle for up to 35 cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A: Favezelimab Dose C+Pembrolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive 200 mg pembrolizumab by IV infusion followed by favezelimab Dose C by IV infusion on Day 1 of each 3-week cycle for up to 35 cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: cHL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with cHL receive 200 mg pembrolizumab by IV infusion followed by the RPTD of favezelimab by IV infusion on Day 1 of each 3-week cycle for up to 35 cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: DLBCL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with DLBCL receive 200 mg pembrolizumab by IV infusion followed by the RPTD of favezelimab by IV infusion on Day 1 of each 3-week cycle for up to 35 cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: iNHL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with iNHL receive 200 mg pembrolizumab by IV infusion followed by the RPTD of favezelimab by IV infusion on Day 1 of each 3-week cycle for up to 35 cycles.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>pembrolizumab</intervention_name>
    <description>Administered as an IV infusion every 3 weeks (Q3W)</description>
    <arm_group_label>Part A: Favezelimab Dose A+pembrolizumab</arm_group_label>
    <arm_group_label>Part A: Favezelimab Dose B+pembrolizumab</arm_group_label>
    <arm_group_label>Part A: Favezelimab Dose C+Pembrolizumab</arm_group_label>
    <arm_group_label>Part B: DLBCL</arm_group_label>
    <arm_group_label>Part B: cHL</arm_group_label>
    <arm_group_label>Part B: iNHL</arm_group_label>
    <other_name>KEYTRUDA®</other_name>
    <other_name>MK-3475</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Favezelimab</intervention_name>
    <description>Administered as an IV infusion Q3W</description>
    <arm_group_label>Part A: Favezelimab Dose A+pembrolizumab</arm_group_label>
    <arm_group_label>Part A: Favezelimab Dose B+pembrolizumab</arm_group_label>
    <arm_group_label>Part A: Favezelimab Dose C+Pembrolizumab</arm_group_label>
    <arm_group_label>Part B: DLBCL</arm_group_label>
    <arm_group_label>Part B: cHL</arm_group_label>
    <arm_group_label>Part B: iNHL</arm_group_label>
    <other_name>MK-4280</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Has measureable disease, defined as ≥1 lesion that can be accurately measured in 2&#xD;
             dimensions with diagnostic quality cross sectional anatomic imaging (computed&#xD;
             tomography or magnetic resonance imaging). Minimum measurement must be &gt;15 mm in the&#xD;
             longest diameter or &gt;10 mm in the short axis&#xD;
&#xD;
          -  Is able to provide a core or excisional tumor biopsy for biomarker analysis from an&#xD;
             archival (within 3 months) or newly obtained biopsy at screening&#xD;
&#xD;
          -  Has a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Has known clinically active central nervous system (CNS) involvement&#xD;
&#xD;
          -  Has received prior therapy with an anti-lymphocyte activation gene-3 (LAG-3) antibody&#xD;
&#xD;
          -  Has received chimeric antigen receptors (CAR)-T-cell therapy&#xD;
&#xD;
          -  Has received prior anticancer therapy or thoracic radiation therapy within 14 days&#xD;
             before the first dose of study treatment&#xD;
&#xD;
          -  Has ≥Grade 2 non-hematological toxicities from prior therapy&#xD;
&#xD;
          -  Has had a prior anticancer monoclonal antibody within 4 weeks prior to study Day 1 or&#xD;
             who has not recovered (i.e., ≤Grade 1 or at baseline) from AEs due to agents&#xD;
             administered ≥4 weeks earlier&#xD;
&#xD;
          -  Has received a live vaccine within 30 days prior to first dose of study treatment&#xD;
&#xD;
          -  Is currently participating and receiving study therapy or has participated in a study&#xD;
             of an investigational agent and received study therapy or used an investigational&#xD;
             device within 28 days before study Day 1&#xD;
&#xD;
          -  Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy&#xD;
             or any other form of immunosuppressive therapy within 7 days prior the first dose of&#xD;
             study drug&#xD;
&#xD;
          -  Has a known additional malignancy that is progressing or requires active treatment&#xD;
             with the exception of basal cell carcinoma of the skin, squamous cell carcinoma of the&#xD;
             skin, or in situ cervical cancer that has undergone potentially curative therapy&#xD;
&#xD;
          -  Has active autoimmune disease that has required systemic treatment in past 2 years&#xD;
             (i.e., with use of disease modifying agents, corticosteroids or immunosuppressive&#xD;
             drugs)&#xD;
&#xD;
          -  Has a history of (non-infectious) pneumonitis that required steroids or current&#xD;
             pneumonitis&#xD;
&#xD;
          -  Has an active infection requiring intravenous systemic therapy&#xD;
&#xD;
          -  Has a known history of human immunodeficiency virus (HIV) infection&#xD;
&#xD;
          -  Has known, active hepatitis B or hepatitis C infection&#xD;
&#xD;
          -  Is pregnant or breastfeeding, or expecting to conceive or father children within the&#xD;
             projected duration of the study, starting with the screening visit through 120 days&#xD;
             after the last dose of study treatment&#xD;
&#xD;
          -  Has had an allogeneic hematopoetic stem cell/solid organ transplantation within the&#xD;
             last 5 years&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Toll Free Number</last_name>
    <phone>1-888-577-8839</phone>
    <email>Trialsites@merck.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Banner MD Anderson Cancer Center ( Site 0020)</name>
      <address>
        <city>Gilbert</city>
        <state>Arizona</state>
        <zip>85234</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>480-256-3425</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>City of Hope ( Site 0001)</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>626-256-2405</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ronald Reagan UCLA Medical Center (Radiological Sciences) ( Site 0007)</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>310-582-4067</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pacific Cancer Care ( Site 0006)</name>
      <address>
        <city>Monterey</city>
        <state>California</state>
        <zip>93940</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>831-375-4105</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of California San Francisco ( Site 0023)</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>415-885-3882</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute ( Site 0002)</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>617-632-2305</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fox Chase Cancer Center ( Site 0019)</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Texas Oncology-Austin Midtown ( Site 8002)</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>281-863-6701</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Concord Repatriation &amp; General Hospital ( Site 0203)</name>
      <address>
        <city>Concord</city>
        <state>New South Wales</state>
        <zip>2139</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+61397677341</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Princess Alexandra Hospital ( Site 0204)</name>
      <address>
        <city>Woollongabba</city>
        <state>Queensland</state>
        <zip>4102</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+61731766826</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Monash Health ( Site 0201)</name>
      <address>
        <city>Clayton</city>
        <state>Victoria</state>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+61395946666</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>St Vincent s Hospital (Melbourne) Limited ( Site 0202)</name>
      <address>
        <city>Fitzroy</city>
        <state>Victoria</state>
        <zip>3065</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+61398593936</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>BC Cancer ( Site 0107)</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 1L3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>6048776000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CancerCare Manitoba ( Site 0101)</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3E 0V9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>2047874156</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Cancer Centre ( Site 0100)</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>4169464501</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jewish General Hospital ( Site 0105)</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>5143408222 x 24572</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>U. klinikum Koeln AOER ( Site 0326)</name>
      <address>
        <city>Koeln</city>
        <state>Nordrhein-Westfalen</state>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+4922147897657</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Leipzig AOeR ( Site 0327)</name>
      <address>
        <city>Leipzig</city>
        <state>Sachsen</state>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+493419720363</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rambam Medical Center ( Site 0382)</name>
      <address>
        <city>Haifa</city>
        <zip>3109601</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+97247773109</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hadassah Ein Karem Jerusalem ( Site 0383)</name>
      <address>
        <city>Jerusalem</city>
        <zip>9112001</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+97226778243</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chaim Sheba Medical Center. ( Site 0380)</name>
      <address>
        <city>Ramat Gan</city>
        <zip>5262001</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+97235302588</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sourasky Medical Center ( Site 0381)</name>
      <address>
        <city>Tel Aviv</city>
        <zip>6423906</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+97236973782</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>A.O. Universitaria Policlinico S. Orsola-Malpighi ( Site 0351)</name>
      <address>
        <city>Bologna</city>
        <state>Emilia-Romagna</state>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+390516363680</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori ( Site 0354)</name>
      <address>
        <city>Meldola</city>
        <state>Forli-Cesena</state>
        <zip>47014</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+390543739290</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istituto Clinico Humanitas Research Hospital ( Site 0352)</name>
      <address>
        <city>Rozzano</city>
        <state>Lombardia</state>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+390282244080</phone>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>July 16, 2018</study_first_submitted>
  <study_first_submitted_qc>July 16, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 26, 2018</study_first_posted>
  <last_update_submitted>November 11, 2021</last_update_submitted>
  <last_update_submitted_qc>November 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>programmed cell death 1 (PD-1, PD1)</keyword>
  <keyword>programmed cell death ligand 1 (PD-L1, PDL1)</keyword>
  <keyword>programmed cell death ligand 2 (PD-L2, PDL2)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Hematologic Neoplasms</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf</ipd_description>
    <ipd_url>http://engagezone.msd.com/ds_documentation.php</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

